Diaceutics PLC Issue of Share Options/PDMR Shareholdings
July 29 2024 - 2:00AM
RNS Regulatory News
RNS Number : 1122Y
Diaceutics PLC
29 July 2024
Diaceutics PLC
Issue of Share Options/PDMR
Shareholdings
Belfast and
London, 29 July 2024- Diaceutics PLC (AIM:
DXRX), a leading technology and solutions provider to the pharma
and biotech industry, announces
the issue of 1,494,051 share options over ordinary shares of
£0.002 each in the Company ("Share
Options") to certain directors, members of the Company's
senior management team and other key staff, pursuant to the
Company's Employee Share Option Plan ("ESOP") on 23 July 2024. These awards
are made in accordance with the Company's long term incentive plan
as detailed in the Company's Annual Report.
Share Options were granted as to PDMRs
follows:
Name
|
Number of Share Options
granted
|
Total no. of ordinary shares under
option post grant
|
% of existing issued share
capital
|
Effective Grant date
|
Ryan Keeling, CEO
|
236,250
|
581,947
|
0.69%
|
23 July
2024
|
Nick Roberts, CFO
|
168,750
|
327,622
|
0.39%
|
23 July
2024
|
Julie Browne, COO and PDMR
|
76,631
|
245,678
|
0.29%
|
23 July
2024
|
Jordan Clark, CDO and PDMR
|
74,502
|
190,242
|
0.22%
|
23 July
2024
|
Susanne Munksted, CPO and PDMR
|
74,647
|
284,829
|
0.34%
|
23 July
2024
|
Jillian Beggs, CCO and PDMR
|
72,844
|
129,548
|
0.15%
|
23 July
2024
|
A further 790,927 Share Options were granted to
a total of 53 other employees.
The Share Options vest on a sliding scale up to
100%, after three years from the date of grant (the "Performance Period"), subject to the
satisfaction of certain performance criteria. The performance
criteria are based upon the growth during the Performance Period in
Total Shareholder Return ("TSR"), the revenue Compound Annual
Growth Rate ("CAGR") and
recurring revenue. The average mid-market closing share price in
the three days prior to the issue of the Share Options was £1.33.
The exercise price of the Share Options is £0.002 per share which
equates to the nominal value of the ordinary shares.
Following this grant, the total number of share
options outstanding in the Company is 4,711,454 representing
approximately 5.56% of its current issued share capital of
84,720,076.
Enquiries:
Diaceutics
PLC
|
|
Nick Roberts, Chief Financial
Officer
|
Tel: +44 (0)28 9040
6500
investorrelations@diaceutics.com
|
|
|
|
|
Stifel
Nicolaus Europe Limited (Nomad & Broker)
|
Tel: +44 (0)20 7710
7600
|
Ben Maddison
Nick Harland
Kate Hanshaw
|
|
|
|
Alma Strategic
Communications
|
Tel: +44(0)20 3405
0205
|
Caroline Forde,
Kinvara Verdon
Kieran Breheny
|
diaceutics@almastrategic.com
|
About
Diaceutics
At Diaceutics we believe that every
patient should get the opportunity to receive the right test and
the right therapy to positively impact their disease
outcome.
We provide the world's leading
pharma and biotech companies with an end-to-end commercialisation
solution for precision medicines through data analytics, scientific
and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Ryan Keeling
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Chief Executive Officer
|
b.
|
Initial notification/
Amendment
|
Initial
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Diaceutics PLC
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Options over new ordinary shares
of 0.2p
each
ISIN:
GB00BJQTGV64
|
b.
|
Nature of the transaction
|
Grant of share options
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
Exercise price of 0.2p per share
|
236,250
|
|
|
e.
|
Date of the transaction
|
23 July 2024
|
f.
|
Place of the transaction
|
Outside a trading venue
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Nick Roberts
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Chief Finance Officer
|
b.
|
Initial notification/
Amendment
|
Initial
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Diaceutics PLC
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Options over new ordinary shares
of 0.2p
each
ISIN:
GB00BJQTGV64
|
b.
|
Nature of the transaction
|
Grant of share options
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
Exercise price of 0.2p per share
|
168,750
|
|
|
e.
|
Date of the transaction
|
23 July 2024
|
f.
|
Place of the transaction
|
Outside a trading venue
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Julie Browne
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Chief Operations Officer
|
b.
|
Initial notification/
Amendment
|
Initial
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Diaceutics PLC
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Options over new ordinary shares
of 0.2p
each
ISIN:
GB00BJQTGV64
|
b.
|
Nature of the transaction
|
Grant of share options
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
Exercise price of 0.2p per share
|
76,631
|
|
|
e.
|
Date of the transaction
|
23 July 2024
|
f.
|
Place of the transaction
|
Outside a trading venue
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Jordan Clark
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Chief Data Officer
|
b.
|
Initial notification/
Amendment
|
Initial
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Diaceutics PLC
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Options over new ordinary shares
of 0.2p
each
ISIN:
GB00BJQTGV64
|
b.
|
Nature of the transaction
|
Grant of share options
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
Exercise price of 0.2p per share
|
74,502
|
|
|
e.
|
Date of the transaction
|
23 July 2024
|
f.
|
Place of the transaction
|
Outside a trading venue
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Susanne Munksted
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Chief Precision Medicine Officer
|
b.
|
Initial notification/
Amendment
|
Initial
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Diaceutics PLC
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Options over new ordinary shares
of 0.2p
each
ISIN:
GB00BJQTGV64
|
b.
|
Nature of the transaction
|
Grant of share options
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
Exercise price of 0.2p per share
|
74,647
|
|
|
e.
|
Date of the transaction
|
23 July 2024
|
f.
|
Place of the transaction
|
Outside a trading venue
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Jillian Beggs
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Chief Commercial Officer
|
b.
|
Initial notification/
Amendment
|
Initial
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Diaceutics PLC
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Options over new ordinary shares
of 0.2p
each
ISIN:
GB00BJQTGV64
|
b.
|
Nature of the transaction
|
Grant of share options
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
Exercise price of 0.2p per share
|
72,844
|
|
|
e.
|
Date of the transaction
|
23 July 2024
|
f.
|
Place of the transaction
|
Outside a trading venue
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHBVLLLZDLBBBD
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024